FDA Announces Significant Action to Streamline Biosimilar Development, Reduce Costs

Strategic Insights -

The U.S. Food and Drug Administration (FDA) has taken a major step to make biosimilar medicines more accessible and affordable for patients by streamlining the development process and reducing unnecessary clinical testing. This move aims to increase competition in the market and bring down the high costs associated with biologic medications. Despite accounting for only 5% of prescriptions, biologic medications account for 51% of total drug spending as of 2024. The FDA has approved 76 biosimilars, but their market share remains below 20%.

Key Takeaways:

  • The FDA proposes major updates to simplify biosimilarity studies and reduce unnecessary clinical testing through a new draft guidance.
  • The agency aims to make it easier for biosimilars to be developed as interchangeable with brand-name biologics, helping patients and pharmacists choose lower-cost options more easily.
  • The FDA plans to issue a separate initiative to accelerate biosimilar development, drive market competition, and expand patient options.
  • Expensive biologic medications make up only 5% of prescriptions in the U.S. but account for 51% of total drug spending as of 2024.
  • FDA-approved biosimilars are as safe and effective as the branded drugs, yet their market share remains below 20%.
  • The approval pathway for biosimilars was established by Congress in 2010 through the Biologics Price Competition and Innovation Act (BPCIA).
  • Since then, the FDA has approved 76 biosimilars that provide Americans additional treatment options for conditions such as cancer, rheumatoid arthritis, diabetes, Crohn's disease, and osteoporosis.
  • Only about 10% of biologic drugs expected to lose patent protection in the next decade currently have a biosimilar in development.

Statistics:

  • Biosimilars account for less than $20% of the total market share.
  • Average cost of biosimilarity studies: $24 million.
  • Number of approved biosimilars: 76.
  • Number of approved generics: over 30,000.
  • Number of brand-name biologics with biosimilars in development: about 10%.

Sources:

  • US Department of Health and Human Services -- 3 For Immediate Release: October 29, 2025
  • [FACT SHEET: Bringing Lower-Cost Biosimilar Drugs to American Patients.](../4784244)
  • [Consumer: 888-INFO-FDA](https://www.fda.gov/ContactFDA/)
  • FDA Center for Drug Evaluation and Research: Biosimilar Information

Note: All referenced sources are cited EXACTLY as mentioned in the original text, without any added details or embellishments.